What is Faeth Therapeutics, Inc's earnings per share (EPS)?

Faeth Therapeutics, Inc (FTH) reported diluted earnings per share of $-16.72 for fiscal year 2025. This represents a 30.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Faeth Therapeutics, Inc Financials

FTH

Source SEC Filings (10-K/10-Q) Data as of Jun 30, 2026 Currency USD FYE December

This page shows Faeth Therapeutics, Inc (FTH) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI FTH FY2025 2026-08-04

Faeth’s filings show a cash-burn model where losses convert almost one-for-one into cash use.

In FY2025, operating cash burn of -$20.5M was nearly the same as net loss of -$21.1M, which means accounting losses are closely matching the actual cash drain. That matters because capex was just $16K and cash ended at $8.7M, so the balance sheet is being consumed mainly to fund ongoing operations rather than asset buildout.

The burn rate improved over the last three valid years: free cash outflow moved from -$32.2M in FY2023 to -$20.5M in FY2025. But total assets fell from $74.4M to $22.9M over the same span, showing that narrower losses have not yet stopped balance-sheet consumption.

Near-term liquidity still looks better than leverage: FY2025 current assets were about 5.1x current liabilities, and total liabilities were only $4.3M. Even so, that buffer is thinner than FY2024, when the current ratio was 7.7x and cash was $10.0M, so financial flexibility is narrowing despite a still-light liability load.

Financial Health Signals

Financial health score pending refresh

We are recalculating Faeth Therapeutics, Inc's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.

Piotroski F-Score Partial

1/6

Faeth Therapeutics, Inc passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

0.97x

For every $1 of reported earnings, Faeth Therapeutics, Inc generates $0.97 in operating cash flow (-$20.5M OCF vs -$21.1M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-696.5x

Faeth Therapeutics, Inc earns $-696.5 in operating income for every $1 of interest expense (-$22.3M vs $32K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$22.2M

YoY+30.9%

Faeth Therapeutics, Inc's EBITDA was -$22.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 30.9% from the prior year.

Net Income

-$21.1M

YoY+30.1%

Faeth Therapeutics, Inc reported -$21.1M in net income in fiscal year 2025. This represents an increase of 30.1% from the prior year.

EPS (Diluted)

$-16.72

YoY+30.4%

Faeth Therapeutics, Inc earned $-16.72 per diluted share (EPS) in fiscal year 2025. This represents an increase of 30.4% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$20.5M

YoY+17.5%

Faeth Therapeutics, Inc generated -$20.5M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 17.5% from the prior year.

Cash & Debt

$8.7M

YoY-13.3%

5Y CAGR-12.2%

Faeth Therapeutics, Inc held $8.7M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

YoY+0.2%

Faeth Therapeutics, Inc had 1M shares outstanding in fiscal year 2025. This represents an increase of 0.2% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-113.4%

YoY-34.9pp

Faeth Therapeutics, Inc's ROE was -113.4% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 34.9 percentage points from the prior year.

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

$16K

YoY-89.0%

5Y CAGR-57.9%

Faeth Therapeutics, Inc invested $16K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 89.0% from the prior year.

FTH Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$11.3M-13.1%	$13.0M-30.5%	$18.8M-5.3%	$19.8M+25.2%	$15.8M+110.1%	$7.5M
Operating Income	-$22.3M+31.7%	-$32.6M+12.0%	-$37.1M+26.1%	-$50.2M-33.9%	-$37.5M-92.7%	-$19.5M
Interest Expense	$32K-64.4%	$90K-37.5%	$144K-34.2%	$219K-67.3%	$670K-60.3%	$1.7M
Income Tax	$0	$0	N/A	N/A	N/A	N/A
Net Income	-$21.1M+30.1%	-$30.2M+11.6%	-$34.1M+29.8%	-$48.6M-32.1%	-$36.8M-83.1%	-$20.1M
EPS (Diluted)	$-16.72+30.4%	$-24.01	$-1.22+22.8%	$-1.58-18.8%	$-1.33	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$9.2M-53.3%	$19.7M	N/A	$2.3M-13.4%	$2.7M-24.7%	$3.5M	N/A	$3.2M
Operating Income	-$18.4M+89.2%	-$170.6M	N/A	-$4.9M+6.8%	-$5.2M+28.4%	-$7.3M	N/A	-$7.8M
Interest Expense	N/A	N/A	N/A	$6K-40.0%	$10K-23.1%	$13K	N/A	$21K
Income Tax	$0	$0	N/A	N/A	$0	$0	N/A	N/A
Net Income	-$16.0M+90.6%	-$170.2M	N/A	-$4.6M+7.4%	-$4.9M+28.1%	-$6.9M	N/A	-$7.3M
EPS (Diluted)	$-2.84	$-131.45	N/A	$-3.62+7.4%	$-3.91	$-5.45	N/A	$-5.77

FTH Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$22.9M-49.5%	$45.4M-39.0%	$74.4M-37.2%	$118.4M-22.7%	$153.2M+615.1%	$21.4M
Current Assets	$21.5M-48.7%	$41.9M-37.7%	$67.3M-38.1%	$108.6M-26.9%	$148.5M+639.9%	$20.1M
Cash & Equivalents	$8.7M-13.3%	$10.0M-23.2%	$13.0M-26.9%	$17.8M+148.6%	$7.2M-56.9%	$16.6M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$4.3M-38.2%	$7.0M-26.4%	$9.5M-36.7%	$15.0M+123.0%	$6.7M-91.4%	$77.9M
Current Liabilities	$4.3M-22.0%	$5.4M-3.5%	$5.6M-37.8%	$9.1M+85.4%	$4.9M+1.2%	$4.8M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	$567K
Total Equity	$18.6M-51.6%	$38.4M-40.8%	$64.9M-37.2%	$103.4M-29.4%	$146.5M+359.6%	-$56.4M
Retained Earnings	-$283.1M-8.0%	-$262.1M-13.0%	-$231.9M-17.2%	-$197.8M-32.6%	-$149.2M-32.7%	-$112.4M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$189.3M-7.8%	$205.4M+796.8%	$22.9M-17.0%	$27.6M-13.2%	$31.8M-17.0%	$38.3M-15.6%	$45.4M-14.8%	$53.3M
Current Assets	$188.7M-7.6%	$204.2M+849.6%	$21.5M-16.6%	$25.8M-12.8%	$29.6M-17.1%	$35.7M-14.9%	$41.9M-12.8%	$48.1M
Cash & Equivalents	$26.9M-82.3%	$152.3M+1657.3%	$8.7M-17.9%	$10.6M-15.9%	$12.6M+27.1%	$9.9M-1.2%	$10.0M-47.8%	$19.1M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	$0	$0	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$9.6M-97.2%	$342.7M+7850.5%	$4.3M-5.9%	$4.6M+2.5%	$4.5M-28.9%	$6.3M-9.9%	$7.0M-6.7%	$7.5M
Current Liabilities	$9.6M-32.5%	$14.2M+233.8%	$4.3M-4.2%	$4.4M+14.5%	$3.9M-25.9%	$5.2M-4.0%	$5.4M+0.1%	$5.4M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$173.0M+226.0%	-$137.3M-838.4%	$18.6M-19.2%	$23.0M-15.8%	$27.3M-14.6%	$32.0M-16.7%	$38.4M-16.1%	$45.8M
Retained Earnings	-$469.4M-3.5%	-$453.4M-60.1%	-$283.1M-1.7%	-$278.4M-1.7%	-$273.9M-1.8%	-$268.9M-2.6%	-$262.1M-3.1%	-$254.3M

FTH Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$20.5M+17.1%	-$24.7M+23.0%	-$32.0M+17.9%	-$39.0M-29.0%	-$30.3M-70.9%	-$17.7M
Capital Expenditures	$16K-89.0%	$146K-18.9%	$180K-43.9%	$321K-84.2%	$2.0M+68.0%	$1.2M
Free Cash Flow	-$20.5M+17.5%	-$24.8M+22.9%	-$32.2M+18.2%	-$39.3M-21.9%	-$32.3M-70.7%	-$18.9M
Investing Cash Flow	$19.8M-11.9%	$22.4M-41.6%	$38.4M-23.1%	$49.9M+134.9%	-$143.1M-10100.9%	-$1.4M
Financing Cash Flow	-$645K+18.0%	-$787K+93.0%	-$11.2M-3793.0%	-$287K-100.2%	$163.9M+362.4%	$35.5M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	$10.4M	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$15.7M-46.0%	-$10.7M-177.8%	-$3.9M-7.8%	-$3.6M+39.3%	-$5.9M+16.7%	-$7.1M-22.5%	-$5.8M-5.9%	-$5.5M
Capital Expenditures	$0-100.0%	$6K	$0	$0-100.0%	$16K	$0	$0	$0
Free Cash Flow	-$15.7M-45.9%	-$10.7M-177.9%	-$3.9M-7.8%	-$3.6M+39.5%	-$5.9M+16.5%	-$7.1M-22.5%	-$5.8M-5.9%	-$5.5M
Investing Cash Flow	-$108.1M-243.8%	-$31.4M-1610.6%	$2.1M+19.4%	$1.7M-80.1%	$8.8M+21.8%	$7.2M+328.2%	-$3.2M-124.4%	$12.9M
Financing Cash Flow	-$1.7M-100.9%	$185.8M+167510.8%	-$111K+27.0%	-$152K+9.5%	-$168K+21.5%	-$214K-10.3%	-$194K+4.9%	-$204K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

FTH Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-113.4%-34.9pp	-78.6%-26.0pp	-52.5%-5.6pp	-47.0%-21.9pp	-25.1%	N/A
Return on Assets	-92.1%-25.6pp	-66.5%-20.6pp	-45.9%-4.8pp	-41.0%-17.0pp	-24.0%+69.8pp	-93.8%
Current Ratio	5.06-2.6	7.70-4.2	11.92-0.1	11.98-18.4	30.38+26.2	4.16
Debt-to-Equity	0.23+0.1	0.18+0.0	0.150.0	0.14+0.1	0.05	N/A
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-9.3%	N/A	N/A	-19.9%-1.8pp	-18.1%+3.4pp	-21.5%	N/A	-15.8%
Return on Assets	-8.5%+74.4pp	-82.9%	N/A	-16.6%-1.0pp	-15.5%+2.4pp	-17.9%	N/A	-13.6%
Current Ratio	19.69+5.3	14.39+9.3	5.06-0.8	5.81-1.8	7.64+0.8	6.82-0.9	7.70-1.1	8.84
Debt-to-Equity	0.06	N/A	0.23+0.0	0.20+0.0	0.16-0.0	0.20+0.0	0.18+0.0	0.16
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Frequently Asked Questions

Is Faeth Therapeutics, Inc profitable?

No, Faeth Therapeutics, Inc (FTH) reported a net income of -$21.1M in fiscal year 2025.

What is Faeth Therapeutics, Inc's EBITDA?

Faeth Therapeutics, Inc (FTH) had EBITDA of -$22.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Faeth Therapeutics, Inc's return on equity (ROE)?

Faeth Therapeutics, Inc (FTH) has a return on equity of -113.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Faeth Therapeutics, Inc's free cash flow?

Faeth Therapeutics, Inc (FTH) generated -$20.5M in free cash flow during fiscal year 2025. This represents a 17.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Faeth Therapeutics, Inc's operating cash flow?

Faeth Therapeutics, Inc (FTH) generated -$20.5M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Faeth Therapeutics, Inc's total assets?

Faeth Therapeutics, Inc (FTH) had $22.9M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Faeth Therapeutics, Inc's capital expenditures?

Faeth Therapeutics, Inc (FTH) invested $16K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How many shares does Faeth Therapeutics, Inc have outstanding?

Faeth Therapeutics, Inc (FTH) had 1M shares outstanding as of fiscal year 2025.

What is Faeth Therapeutics, Inc's current ratio?

Faeth Therapeutics, Inc (FTH) had a current ratio of 5.06 as of fiscal year 2025, which is generally considered healthy.

What is Faeth Therapeutics, Inc's debt-to-equity ratio?

Faeth Therapeutics, Inc (FTH) had a debt-to-equity ratio of 0.23 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Faeth Therapeutics, Inc's return on assets (ROA)?

Faeth Therapeutics, Inc (FTH) had a return on assets of -92.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Faeth Therapeutics, Inc's cash runway?

Based on fiscal year 2025 data, Faeth Therapeutics, Inc (FTH) had $8.7M in cash against an annual operating cash burn of $20.5M. This gives an estimated cash runway of approximately 5 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Faeth Therapeutics, Inc's Piotroski F-Score?

Faeth Therapeutics, Inc (FTH) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Faeth Therapeutics, Inc's earnings high quality?

Faeth Therapeutics, Inc (FTH) has an earnings quality ratio of 0.97x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Faeth Therapeutics, Inc cover its interest payments?

Faeth Therapeutics, Inc (FTH) has an interest coverage ratio of -696.5x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.